Skip to main content

Table 5 Genotype frequencies and effects of BDNF-associated variants on CKD

From: Brain-derived neurotrophic factor associated with kidney function

 

Case (n = 167) and control (n = 1105)*

All enrolled participants (N = 2997)#

SNP

MAF

Genotype

Case N (%)

Control N (%)

P

Model†

OR/B‡ 95% CI

P

rs12098908

0.142

CC

135 (83.3%)

778 (72.4%)

0.004

Dominant

0.733 (0.601, 0.895)

0.002

  

CT

22 (13.6%)

272 (25.3%)

 

Recessive

0.710 (0.386, 1.306)

0.271

  

TT

5 (3.1%)

24 (2.2%)

 

Additive

− 0.047 (− 0.079, − 0.016)

0.003

rs12577517

0.151

AA

135 (80.8%)

783 (70.9%)

0.006

Dominant

0.802 (0.663, 0.969)

0.022

  

AG

26 (15.6%)

297 (26.9%)

 

Recessive

0.847 (0.479, 1.500)

0.570

  

GG

6 (3.6%)

25 (2.3%)

 

Additive

− 0.032 (− 0.063, − 0.002)

0.039

rs6265

0.500

CC

45 (27.1%)

277 (25.0%)

0.309

   
  

CT

73 (44.0%)

555 (50.2%)

    
  

TT

48 (28.9%)

274 (24.8%)

    

rs72891405

0.151

CC

135 (80.8%)

783 (70.9%)

0.006

Dominant

0.800 (0.662, 0.967)

0.021

  

CT

26 (15.6%)

297 (26.9%)

 

Recessive

0.846 (0.478, 1.498)

0.567

  

TT

6 (3.6%)

25 (2.3%)

 

Additive

− 0.033 (− 0.063, − 0.002)

0.037

  1. *Case means age < 60 years with CKD; control means age ≥ 60 years but without CKD
  2. #Analyses were not performed on rs6265 as there was no significant difference in case–control assessment
  3. †Adjusted for age and sex. ‡OR = odds ratio for the dominant and recessive models, and B = regression coefficient in the additive model
  4. BDNF brain-derived neurotrophic factor, CKD chronic kidney disease, MAF minor allele frequency, SNP single nucleotide polymorphism
Back to article page

Diabetology & Metabolic Syndrome

ISSN: 1758-5996

Contact us